These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 17700222

  • 1. Fluvastatin blunts the effect of a high-fat meal on plasma triglyceride and high-sensitivity C-reactive protein concentrations in patients at high risk for cardiovascular events.
    Liu L, Zhao SP, Hu M, Li JX.
    Coron Artery Dis; 2007 Sep; 18(6):489-93. PubMed ID: 17700222
    [Abstract] [Full Text] [Related]

  • 2. [Effect of valsartan on postprandial plasma inflammatory factors in patients with essential hypertension].
    Liu L, Zhao SP, Zhou HN, Xu DY, Li JX.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 33(9):809-13. PubMed ID: 18812659
    [Abstract] [Full Text] [Related]

  • 3. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
    Liu L, Zhao SP, Zhou HN, Li QZ, Li JX.
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
    [Abstract] [Full Text] [Related]

  • 4. Postprandial hypertriglyceridemia associated with inflammatory response and procoagulant state after a high-fat meal in hypertensive patients.
    Liu L, Zhao SP, Wen T, Zhou HN, Hu M, Li JX.
    Coron Artery Dis; 2008 May; 19(3):145-51. PubMed ID: 18418230
    [Abstract] [Full Text] [Related]

  • 5. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 6. Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin.
    Lye M, Valacio R, Reckless JP, Ghosh AK, Findlay IN, Ghosh MK, Passmore AP, Fulcher RA.
    Coron Artery Dis; 1998 Jan; 9(9):583-90. PubMed ID: 9861520
    [Abstract] [Full Text] [Related]

  • 7. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials.
    Winkler K, Ablethauser CB, Gimpelewicz C, Bortolini M, Isaacsohn JL.
    Clin Ther; 2007 Sep; 29(9):1987-2000. PubMed ID: 18035198
    [Abstract] [Full Text] [Related]

  • 8. Comparison of lycopene and fluvastatin effects on atherosclerosis induced by a high-fat diet in rabbits.
    Hu MY, Li YL, Jiang CH, Liu ZQ, Qu SL, Huang YM.
    Nutrition; 2008 Oct; 24(10):1030-8. PubMed ID: 18585898
    [Abstract] [Full Text] [Related]

  • 9. Effect of weight loss on the postprandial response to high-fat and high-carbohydrate meals in obese women.
    Dallongeville J, Gruson E, Dallinga-Thie G, Pigeyre M, Gomila S, Romon M.
    Eur J Clin Nutr; 2007 Jun; 61(6):711-8. PubMed ID: 17228347
    [Abstract] [Full Text] [Related]

  • 10. Response of high-sensitivity C-reactive protein to exercise training in an at-risk population.
    Huffman KM, Samsa GP, Slentz CA, Duscha BD, Johnson JL, Bales CW, Tanner CJ, Houmard JA, Kraus WE.
    Am Heart J; 2006 Oct; 152(4):793-800. PubMed ID: 16996860
    [Abstract] [Full Text] [Related]

  • 11. The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia.
    Sonmez A, Dogru T, Tasci I, Yilmaz MI, Pinar M, Naharci I, Bingol N, Kilic S, Demirtas A, Bingol S, Ozgurtas T, Erikci S.
    Clin Endocrinol (Oxf); 2006 May; 64(5):567-72. PubMed ID: 16649978
    [Abstract] [Full Text] [Related]

  • 12. The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome.
    Yang J, Li XP, Zhao SP, Li J, Li JD, Xie XM.
    Clin Chim Acta; 2006 Jun; 368(1-2):183-7. PubMed ID: 16472797
    [Abstract] [Full Text] [Related]

  • 13. Comparison of efficacy and safety assessment of fluvastatin in patients <65 years versus > or =65 years of age.
    Bruckert E, Verpilleux MP, Dejager S, Isaacsohn J.
    Am J Cardiol; 2005 Oct 15; 96(8):1142-8. PubMed ID: 16214453
    [Abstract] [Full Text] [Related]

  • 14. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
    Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Olijhoek JK, Visseren FL.
    Clin Endocrinol (Oxf); 2008 Dec 15; 69(6):870-7. PubMed ID: 18394022
    [Abstract] [Full Text] [Related]

  • 15. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1994 Dec 15; (77):28-32. PubMed ID: 19496270
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of fluvastatin in hyperlipidaemic patients with non-insulin-dependent diabetes mellitus.
    Jokubaitis LA, Knopp RH, Frohlich J.
    J Intern Med Suppl; 1994 Dec 15; 736():103-7. PubMed ID: 7986302
    [Abstract] [Full Text] [Related]

  • 17. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease.
    Zhao SP, Liu L, Cheng YC, Shishehbor MH, Liu MH, Peng DQ, Li YL.
    Circulation; 2004 Aug 24; 110(8):915-20. PubMed ID: 15313947
    [Abstract] [Full Text] [Related]

  • 18. Fasting triacylglycerol status, but not polyunsaturated/saturated fatty acid ratio, influences the postprandial response to a series of oral fat tolerance tests.
    Dekker MJ, Wright AJ, Mazurak VC, Marangoni AG, Rush JW, Graham TE, Robinson LE.
    J Nutr Biochem; 2009 Sep 24; 20(9):694-704. PubMed ID: 18829281
    [Abstract] [Full Text] [Related]

  • 19. Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease.
    Huang PH, Lu TM, Wu TC, Lin FY, Chen YH, Chen JW, Lin SJ.
    Coron Artery Dis; 2008 May 24; 19(3):187-93. PubMed ID: 18418236
    [Abstract] [Full Text] [Related]

  • 20. Level of high-sensitivity C-reactive protein in Saudi patients with chronic stable coronary artery disease.
    Habib SS.
    J Ayub Med Coll Abbottabad; 2008 May 24; 20(2):3-6. PubMed ID: 19385446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.